drugset
drugset / Trial / NCT06501183

Anti-CDH17 CAR-T Cell Injection in Patients With CDH17-positive Advanced Malignant Solid Tumors

NCT06501183 ↗

Phase 1 Recruiting 17 enrolled Shanghai Pudong Hospital UTC Therapeutics Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, open-label, exploratory clinical study to evaluate the safety and preliminary efficacy of Anti-CDH17 CAR-T cell injection in patients with CDH17-positive advanced malignant solid tumors.

Timeline

Start
2024-07-08
Primary completion
2025-05-30
Completion
2026-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Anti-CDH17 CAR-T cells Cell therapy — Intravenous

Indications

No indication recorded.